Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect

Birgit Grund, Edwina Jane Wright, Bruce J Brew, Richard W Price, Mollie Roediger, Margaret P Bain, Jennifer F Hoy, Judith C Shlay, Michael J Vjecha, Kevin R Robertson

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

We evaluated factors associated with improvement in neurocognitive performance in 258 HIV-infected adults with baseline CD4 lymphocyte counts above 350 cells/mm3 randomized to intermittent, CD4-guided antiretroviral therapy (ART) (128 participants) versus continuous therapy (130) in the Neurology substudy of the Strategies for Management of Antiretroviral Therapy trial. Participants were enrolled in Australia, North America, Brazil, and Thailand, and neurocognitive performance was assessed by a five-test battery at baseline and month 6. The primary outcome was change in the quantitative neurocognitive performance z score (QNPZ-5), the average of the z scores of the five tests. Associations of the 6-month change in test scores with ART use, CD4 cell counts, HIV RNA levels, and other factors were determined using multiple regression models. At baseline, median age was 40 years, median CD4 cell count was 513 cells/mm3, 88 had plasma HIV RNA =400 copies/mL, and mean QNPZ-5 was -0.68. Neurocognitive performance improved in both treatment groups by 6 months; QNPZ-5 scores increased by 0.20 and 0.13 in the intermittent and continuous ART groups, respectively (both P?
Original languageEnglish
Pages (from-to)383 - 392
Number of pages10
JournalJournal of Neurovirology
Volume19
Issue number4
DOIs
Publication statusPublished - 2013

Cite this

Grund, Birgit ; Wright, Edwina Jane ; Brew, Bruce J ; Price, Richard W ; Roediger, Mollie ; Bain, Margaret P ; Hoy, Jennifer F ; Shlay, Judith C ; Vjecha, Michael J ; Robertson, Kevin R. / Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. In: Journal of Neurovirology. 2013 ; Vol. 19, No. 4. pp. 383 - 392.
@article{c8320109f07f4051bf454ec42054a6c3,
title = "Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect",
abstract = "We evaluated factors associated with improvement in neurocognitive performance in 258 HIV-infected adults with baseline CD4 lymphocyte counts above 350 cells/mm3 randomized to intermittent, CD4-guided antiretroviral therapy (ART) (128 participants) versus continuous therapy (130) in the Neurology substudy of the Strategies for Management of Antiretroviral Therapy trial. Participants were enrolled in Australia, North America, Brazil, and Thailand, and neurocognitive performance was assessed by a five-test battery at baseline and month 6. The primary outcome was change in the quantitative neurocognitive performance z score (QNPZ-5), the average of the z scores of the five tests. Associations of the 6-month change in test scores with ART use, CD4 cell counts, HIV RNA levels, and other factors were determined using multiple regression models. At baseline, median age was 40 years, median CD4 cell count was 513 cells/mm3, 88 had plasma HIV RNA =400 copies/mL, and mean QNPZ-5 was -0.68. Neurocognitive performance improved in both treatment groups by 6 months; QNPZ-5 scores increased by 0.20 and 0.13 in the intermittent and continuous ART groups, respectively (both P?",
author = "Birgit Grund and Wright, {Edwina Jane} and Brew, {Bruce J} and Price, {Richard W} and Mollie Roediger and Bain, {Margaret P} and Hoy, {Jennifer F} and Shlay, {Judith C} and Vjecha, {Michael J} and Robertson, {Kevin R}",
year = "2013",
doi = "10.1007/s13365-013-0190-x",
language = "English",
volume = "19",
pages = "383 -- 392",
journal = "Journal of Neurovirology",
issn = "1355-0284",
publisher = "Taylor & Francis",
number = "4",

}

Grund, B, Wright, EJ, Brew, BJ, Price, RW, Roediger, M, Bain, MP, Hoy, JF, Shlay, JC, Vjecha, MJ & Robertson, KR 2013, 'Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect', Journal of Neurovirology, vol. 19, no. 4, pp. 383 - 392. https://doi.org/10.1007/s13365-013-0190-x

Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. / Grund, Birgit; Wright, Edwina Jane; Brew, Bruce J; Price, Richard W; Roediger, Mollie; Bain, Margaret P; Hoy, Jennifer F; Shlay, Judith C; Vjecha, Michael J; Robertson, Kevin R.

In: Journal of Neurovirology, Vol. 19, No. 4, 2013, p. 383 - 392.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect

AU - Grund, Birgit

AU - Wright, Edwina Jane

AU - Brew, Bruce J

AU - Price, Richard W

AU - Roediger, Mollie

AU - Bain, Margaret P

AU - Hoy, Jennifer F

AU - Shlay, Judith C

AU - Vjecha, Michael J

AU - Robertson, Kevin R

PY - 2013

Y1 - 2013

N2 - We evaluated factors associated with improvement in neurocognitive performance in 258 HIV-infected adults with baseline CD4 lymphocyte counts above 350 cells/mm3 randomized to intermittent, CD4-guided antiretroviral therapy (ART) (128 participants) versus continuous therapy (130) in the Neurology substudy of the Strategies for Management of Antiretroviral Therapy trial. Participants were enrolled in Australia, North America, Brazil, and Thailand, and neurocognitive performance was assessed by a five-test battery at baseline and month 6. The primary outcome was change in the quantitative neurocognitive performance z score (QNPZ-5), the average of the z scores of the five tests. Associations of the 6-month change in test scores with ART use, CD4 cell counts, HIV RNA levels, and other factors were determined using multiple regression models. At baseline, median age was 40 years, median CD4 cell count was 513 cells/mm3, 88 had plasma HIV RNA =400 copies/mL, and mean QNPZ-5 was -0.68. Neurocognitive performance improved in both treatment groups by 6 months; QNPZ-5 scores increased by 0.20 and 0.13 in the intermittent and continuous ART groups, respectively (both P?

AB - We evaluated factors associated with improvement in neurocognitive performance in 258 HIV-infected adults with baseline CD4 lymphocyte counts above 350 cells/mm3 randomized to intermittent, CD4-guided antiretroviral therapy (ART) (128 participants) versus continuous therapy (130) in the Neurology substudy of the Strategies for Management of Antiretroviral Therapy trial. Participants were enrolled in Australia, North America, Brazil, and Thailand, and neurocognitive performance was assessed by a five-test battery at baseline and month 6. The primary outcome was change in the quantitative neurocognitive performance z score (QNPZ-5), the average of the z scores of the five tests. Associations of the 6-month change in test scores with ART use, CD4 cell counts, HIV RNA levels, and other factors were determined using multiple regression models. At baseline, median age was 40 years, median CD4 cell count was 513 cells/mm3, 88 had plasma HIV RNA =400 copies/mL, and mean QNPZ-5 was -0.68. Neurocognitive performance improved in both treatment groups by 6 months; QNPZ-5 scores increased by 0.20 and 0.13 in the intermittent and continuous ART groups, respectively (both P?

UR - http://link.springer.com/article/10.1007%2Fs13365-013-0190-x

U2 - 10.1007/s13365-013-0190-x

DO - 10.1007/s13365-013-0190-x

M3 - Article

VL - 19

SP - 383

EP - 392

JO - Journal of Neurovirology

JF - Journal of Neurovirology

SN - 1355-0284

IS - 4

ER -